ARS Pharmaceuticals
Stock Forecast, Prediction & Price Target
ARS Pharmaceuticals Financial Estimates
ARS Pharmaceuticals Revenue Estimates
ARS Pharmaceuticals EBITDA Estimates
ARS Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $5.50M N/A | $1.31M -76.09% | $30K -97.72% | Avg: $85.45M Low: $79.29M High: $91.60M avg. 284737.76% | Avg: $211.87M Low: $192.71M High: $231.02M avg. 147.94% | Avg: $304.9M Low: $277.33M High: $332.46M avg. 43.90% | Avg: $613.42M Low: $557.95M High: $668.88M avg. 101.18% |
Net Income
% change YoY
| $-20.24M N/A | $-33.98M -67.90% | $-54.36M -59.95% | Avg: $-40.89M Low: $-61.88M High: $2.85M avg. 24.76% | Avg: $40.06M Low: $33.18M High: $42.03M avg. 197.95% | Avg: $50.46M Low: $44.53M High: $56.39M avg. 25.96% | Avg: $215.18M Low: $189.89M High: $240.47M avg. 326.41% |
EBITDA
% change YoY
| $-19.44M N/A | $-35.05M -80.26% | $-67.44M -92.39% | Avg: $-34.62M Low: $-37.11M High: $-32.13M avg. 48.66% | Avg: $-85.84M Low: $-93.61M High: $-78.08M avg. -147.94% | Avg: $-123.54M Low: $-134.71M High: $-112.37M avg. -43.90% | Avg: $-248.55M Low: $-271.02M High: $-226.08M avg. -101.18% |
EPS
% change YoY
| -$0.7 N/A | -$0.85 -21.42% | -$0.57 32.94% | Avg: -$0.38 Low: -$0.65 High: $0.03 avg. 33.33% | Avg: $0.4 Low: $0.35 High: $0.44 avg. 203.94% | Avg: $0.53 Low: $0.47 High: $0.59 avg. 34.17% | Avg: $2.26 Low: $1.99 High: $2.53 avg. 326.41% |
Operating Expenses
% change YoY
| $24.96M N/A | $36.83M 47.56% | $67.55M 83.40% | Avg: $27.17B Low: $25.21B High: $29.12B avg. 40122.54% | Avg: $67.36B Low: $61.27B High: $73.45B avg. 147.94% | Avg: $96.94B Low: $88.18B High: $105.71B avg. 43.90% | Avg: $195.04B Low: $177.41B High: $212.67B avg. 101.18% |
FAQ
What is ARS Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 143.77% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -61.88M, average is -40.89M and high is 2.85M.
What is ARS Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 71257.70% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $79.29M, average is $85.45M and high is $91.60M.
What is ARS Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 149.46% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.65, average is -$0.38 and high is $0.03.
What is the best performing analyst?
In the last twelve months analysts have been covering ARS Pharmaceuticals stock. The most successful analyst is Roanna Ruiz.